Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biktarvy-Brigham and Women's Hospital refers to a specialized formulation of the FDA-approved HIV-1 medication Biktarvy (a fixed-dose combination of bictegravir, emtricitabine, and tenofovir alafenamide) modified with TruTag Technologies' silica microparticle taggants. Developed by Brigham and Women's Hospital, this system is designed to monitor medication adherence in people living with HIV. The silica microparticles are incorporated into the tablet coating and can be scanned using a smartphone camera and a companion app to record adherence events. The underlying medication, Biktarvy, functions by inhibiting HIV-1 replication through the combined action of an integrase strand transfer inhibitor (bictegravir) and two nucleoside reverse transcriptase inhibitors (emtricitabine and tenofovir alafenamide).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Biktarvy-Brigham and Women's Hospital.